Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
Researchers want to find the best dose of TTI-101 that can be used safely alone and with other drugs for cancer. The people in this study have hepatocellular carcinoma (liver cancer) that has metastasized (spread) or is inoperable (surgically unremovable).
Researchers want to find the best dose of ABBV-453 to treat multiple myeloma. The people in this study have multiple myeloma that may have a genetic change and make too much of the BCL2 protein. In addition, their cancer has not responded to treatment or has returned after treatment.
Researchers want to see if tumor-treating fields (TTFields) are safe and practical for people with lung adenocarcinoma before surgery. Lung adenocarcinoma is a type of lung cancer. If you join this study, you will get treatment with TTFields for up to 3 weeks before lung cancer surgery.
The purpose of this study is to find the highest doses of ruxolitinib and duvelisib when given together in patients with T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment. The Food and Drug Administration (FDA) has approved ruxolitinib as a treatment for myelofibrosis and polycythemia vera (other blood disorders). The FDA has approved duvelisib to treat follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The use of these two drugs together in this study is considered investigational.
Researchers want to find the best doses of RMC-6291 and RMC-6236 when given together to treat lung cancer and other types of cancer that have KRAS G12C mutations. The people in this study have advanced non-small cell lung cancer (NSCLC) or colorectal cancer with a gene mutation (change) called KRAS G12C.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Bone scans, computed tomography (CT), and magnetic resonance imaging (MRI) are imaging tests used to assess the spread of cancer in the body and to determine whether anticancer treatments are working. Even with these tests, however, it is sometimes difficult to find exactly where the cancer is located and to determine whether it is growing or shrinking in response to treatment. This difficulty is particularly apparent in patients with advanced prostate cancer that has spread to the bones, as standard CT, MRI, as bone scans are not accurate in assessing cancer in the bones.
Researchers want to see how well selinexor works in people with Wilms' tumor and other solid tumors. The people in this study are children and adults with tumors that depend on a protein called XPO1. XPO1 helps cancer cells grow by getting rid of proteins that can cause those cells to die (tumor suppressor proteins).
A mutation called G12C in a gene called KRAS may promote cancer growth. LY3537982 is an investigational drug that targets the mutated KRAS G12C protein. This targeting action may stop cancer cells from growing and dividing.
